KRTCAP2: A Potential Drug Target and Biomarker (G200185)

Target Name: KRTCAP2

NCBI ID: G200185

KRTCAP2

KRTCAP2: A Potential Drug Target and Biomarker

Keratinocyte-associated protein 2 (KRTCAP2) is a protein that has been identified as a potential drug target and biomarker for various diseases, including skin diseases, autoimmune disorders, and neurodegenerative diseases. KRTCAP2 is a cytoplasmic protein that is expressed in most tissues of the body, including the skin, hair, nails, and nervous system. It is involved in various cellular processes, including cell adhesion, migration, and survival.

The search for new drug targets and biomarkers has become a major focus in modern medicine, and KRTCAP2 is no exception. Several studies have identified KRTCAP2 as a potential drug target, and research is ongoing to determine its potential utility as a biomarker. In this article, we will explore the potential drug target and biomarker properties of KRTCAP2.

Potential Drug Target:

KRTCAP2 has been identified as a potential drug target due to its various functions in cellular processes. It is involved in the regulation of cell adhesion, which is critical for the development and maintenance of tissues and organs. KRTCAP2 helps to maintain the integrity of cell-cell adhesion by regulating the activity of cadherins, which are a family of transmembrane proteins that play a central role in cell-cell adhesion.

In addition to its role in cell adhesion, KRTCAP2 has also been shown to be involved in the regulation of cell migration and survival. It has been shown to promote the migration of cancer cells to new tumors, and it has also been linked to the development of neurodegenerative diseases.

Potential Biomarker:

KRTCAP2 has also been identified as a potential biomarker for several diseases, including skin diseases, autoimmune disorders, and neurodegenerative diseases. Studies have shown that KRTCAP2 is expressed in skin samples of individuals with skin diseases, including dermatitis and psoriasis. Additionally, KRTCAP2 has been shown to be involved in the development of autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis.

In addition to its potential role as a biomarker, KRTCAP2 has also been shown to have therapeutic potential in several diseases. Studies have shown that inhibiting KRTCAP2 can improve the symptoms of skin diseases, including wound healing and skin inflammation. Additionally, inhibiting KRTCAP2 has been shown to be effective in treating autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis.

Current Status:

Currently, there are several ongoing studies to determine the potential utility of KRTCAP2 as a drug target and biomarker. Several studies have shown that KRTCAP2 can be effectively inhibited in cell cultures and animal models, and that this inhibition can lead to improved symptoms of skin diseases and autoimmune disorders.

While more research is needed to fully understand the potential drug target and biomarker properties of KRTCAP2, its identification and characterization are promising developments in the field of drug development. As research continues, we can expect to see more effective treatments for diseases that are currently treated with limited options.

Conclusion:

In conclusion, KRTCAP2 is a protein that has shown promise as a potential drug target and biomarker for a variety of diseases. Its involvement in cell adhesion, cell migration, and survival makes it an attractive target for drug development. Additionally, its potential as a biomarker for skin diseases and autoimmune disorders makes it an important area of research. Further studies are needed to fully understand the potential utility of KRTCAP2 as a drug

Protein Name: Keratinocyte Associated Protein 2

Functions: Subunit of the oligosaccharyl transferase (OST) complex that catalyzes the initial transfer of a defined glycan (Glc(3)Man(9)GlcNAc(2) in eukaryotes) from the lipid carrier dolichol-pyrophosphate to an asparagine residue within an Asn-X-Ser/Thr consensus motif in nascent polypeptide chains, the first step in protein N-glycosylation. N-glycosylation occurs cotranslationally and the complex associates with the Sec61 complex at the channel-forming translocon complex that mediates protein translocation across the endoplasmic reticulum (ER). All subunits are required for a maximal enzyme activity (PubMed:22467853). May be involved in N-glycosylation of APP (amyloid-beta precursor protein). Can modulate gamma-secretase cleavage of APP by enhancing endoprotelysis of PSEN1 (PubMed:21768116)

The "KRTCAP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KRTCAP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets